Pulmonology

Elexacaftor/tezacaftor/ivacaftor and ivacaftor was previously approved for CF patients at least 12 years old.

An expert discussion on categorizing climate change and the impact it will have on health in communities across the globe.

An expert discussion on climate change and air pollution effects on communities, including increased COVID-19 rates.

The newest findings show the TSLP inhibitor is beneficial over 52 weeks in patients aged 12-80 years old.

Meredith McCormack, MD discusses consequences of high air pollution levels in the United States found in the 2021 American Lung Association State of the Air Report.

Climate change health experts Poune Saberi, MD, and Alan S. Greenglass, MD, join Lungcast for a timely discussion on environmental health issues.

Not all individuals with sarcoidosis need to be treated.

The 2021 annual report finds that Los Angeles remains the most polluted US city, while negative impacts of climate change and COVID-19 are both linked to increased pollution rates.

The monoclonal antibody was linked to significant improvements in endoscopic nasal polyp and nasal obstruction symptom visual analogue scale scores.

A trio of experts from the Cleveland Clinic join Dr. Rizzo for a talk on lung transplant trends and challenges in the US.

Ennis James, MD, discusses the challenges and lingering questions associated with sarcoidosis

The non-invasive device uses air pressure pulsations to help open airways and provide clearance of secretions in patients with disease such as COPD, asthma, and cystic fibrosis.

An interview with a phase 2 investigator on the the novel drug's potential in a field it wasn't originally designed to treat.

New phase 2 data from a 24-week assessment suggest the first-in-class drug could benefit exercise and pulmonary-vascular outcomes.

The supplemental approval for Tyvaso comes on the basis of clinical evidence showing benefit for pulmonary and cardiovascular outcomes in adult patients.

The Harmony Transcatheter Pulmonary Valve System is designed to treat adult and pediatric patients with pulmonary valve regurgitation.

On World TB Day, experts from the ALA and CDC reflect on the recent issues of tuberculosis.

In commemoration of World TB Day, a CDC and ALA expert discuss how TB still exists in the country.

CDC tuberculosis lead Dr. Phillip LoBue joins to discuss the past and present issues of the disease, in time for TB Awareness Day on March 24.

Nearly 60% of children with MIS-C are admitted to the hospital for intensive care.

A pooled analysis of sleep disturbance-related outcomes showed the IgE inhibitor significantly benefits a burdensome symptom of CRSwNP.

From interpreting currently-understood risks to managing isolation-induced indoor allergen exposure, asthmatics may have concerns they address with clinicians.

A review of 3 new studies, which indicate the association between severe COVID-19 and the chronic disease is more intricate than previously thought.

The application, submitted by Merck, is based on data from 2 clinical trials evaluating patients with refractory or unexplained chronic cough.

From better education, to remote monitoring and consistent check-ins, clinicians may need to initiate better adherence in their younger, severely ill patients.